Research Analysts Offer Predictions for ANRO FY2025 Earnings

Key Points

• Wedbush has revised its FY2025 earnings per share estimate for Alto Neuroscience to ($2.40), an improvement from the previous estimate of ($2.59).
• Alto Neuroscience recently missed analysts' consensus estimates in its latest earnings report, posting an EPS of ($0.65) compared to expectations of ($0.57).
• Five investment analysts currently rate the stock as a "Buy," while the consensus target price stands at $11.00.

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Equities researchers at Wedbush lifted their FY2025 earnings per share (EPS) estimates for shares of Alto Neuroscience in a research report issued to clients and investors on Tuesday, October 21st. Wedbush analyst L. Chico now expects that the company will earn ($2.40) per share for the year, up from their prior forecast of ($2.59). The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. Wedbush also issued estimates for Alto Neuroscience's Q4 2025 earnings at ($0.54) EPS, Q1 2026 earnings at ($0.43) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($2.23) EPS.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08).

A number of other research firms have also weighed in on ANRO. Chardan Capital initiated coverage on Alto Neuroscience in a research report on Monday, September 29th. They set a "buy" rating and a $15.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Alto Neuroscience in a report on Wednesday, October 8th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Alto Neuroscience in a report on Monday, August 18th. Finally, Robert W. Baird raised their price objective on shares of Alto Neuroscience from $10.00 to $16.00 and gave the company an "outperform" rating in a research note on Monday. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Alto Neuroscience has a consensus rating of "Moderate Buy" and a consensus target price of $11.00.

Alto Neuroscience Stock Down 5.9%

Shares of Alto Neuroscience stock opened at $10.22 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. The company has a 50-day moving average of $4.72 and a 200 day moving average of $3.29. The firm has a market cap of $276.62 million, a price-to-earnings ratio of -4.27 and a beta of 2.00. Alto Neuroscience has a 1 year low of $1.60 and a 1 year high of $12.19.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently modified their holdings of ANRO. SCS Capital Management LLC bought a new stake in Alto Neuroscience during the 1st quarter valued at $144,000. Nuveen LLC purchased a new position in shares of Alto Neuroscience during the first quarter valued at $302,000. AWM Investment Company Inc. increased its position in Alto Neuroscience by 31.1% during the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company's stock valued at $1,948,000 after purchasing an additional 214,153 shares during the period. Citizens Financial Group Inc. RI purchased a new position in Alto Neuroscience during the 1st quarter valued at about $83,000. Finally, Armistice Capital LLC increased its position in Alto Neuroscience by 146.2% during the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company's stock valued at $3,456,000 after purchasing an additional 950,000 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.